WilmerHale Represents Exo Therapeutics in its $78M Series B Financing

WilmerHale Represents Exo Therapeutics in its $78M Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On October 5, 2021, Exo Therapeutics, Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, announced the completion of a $78 million Series B financing. Proceeds will be used to advance therapeutic candidates in oncology and inflammation derived from the company’s proprietary ExoSightTM platform towards proof-of-concept and into the clinic. Additionally, proceeds will be used to expand Exo’s pursuit of new targets with the ExoSight platform.

The WilmerHale team representing Exo Therapeutics was led by Jason Kropp and included Erin Garrity, Sara Uz and Alex Bloom.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel